Skip to main content
SpringerLink
Log in

Prevention of Type 1 Diabetes Mellitus

  • Chapter
  • First Online:
Principles of Diabetes Mellitus

Abstract

Type 1 diabetes (T1D) results from the autoimmune destruction of insulin-producing beta cells in the pancreas. Genetic, metabolic, and environmental factors act together to precipitate the onset of the disease. The excess mortality associated with complications of T1D and the increasing incidence of childhood T1D emphasize the importance of therapeutic strategies to prevent this chronic metabolic disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ludvigsson J. Why diabetes incidence increases – a unifying theory. Ann N Y Acad Sci. 2006;1079:374–382.

    Article  PubMed  Google Scholar 

  2. White F, Rafique G. Diabetes prevalence and projections in South Asia. Lancet. 2002;360:804–805.

    Article  PubMed  Google Scholar 

  3. Fleming DM, Schellevis FG, Van Casteren V. The prevalence of known diabetes in eight European countries. Eur J Public Health. 2004;14:10–14.

    Article  PubMed  CAS  Google Scholar 

  4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.

    Article  PubMed  Google Scholar 

  5. Rich SS, Concannon P, Erlich H, et al. The Type 1 Diabetes Genetics Consortium. Ann N Y Acad Sci. 2006;1079:1–8.

    Article  PubMed  CAS  Google Scholar 

  6. Valdes AM, McWeeney S, Thomson G. HLA class II DR-DQ amino acids and insulin-dependent diabetes mellitus: application of the haplotype method. Am J Hum Genet. 1997;60:717–728.

    PubMed  CAS  Google Scholar 

  7. Bennett ST, Wilson AJ, Cucca F, et al. IDDM2-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. J Autoimmun. 1996;9:415–421.

    Article  PubMed  CAS  Google Scholar 

  8. Nisticò L, Buzzetti R, Pritchard LE, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet. 1996;5:1075–1080.

    Article  PubMed  Google Scholar 

  9. Ladner MB, Bottini N, Valdes AM, Noble JA. Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes. Hum Immunol. 2005;66:60–64.

    Article  PubMed  CAS  Google Scholar 

  10. Bonifacio E, Bingley PJ. Islet autoantibodies and their use in predicting insulin-dependent diabetes. Acta Diabetol. 1997;34:185–193.

    Article  PubMed  CAS  Google Scholar 

  11. Wasserfall CH, Atkinson MA. Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmun Rev. 2006;5:424–428.

    Article  PubMed  CAS  Google Scholar 

  12. Bingley PJ, Williams AJ. Validation of autoantibody assays in type 1 diabetes: workshop programme. Autoimmunity. 2004;37:257–260.

    Article  PubMed  Google Scholar 

  13. Devendra D, Eisenbarth GS. Immunologic endocrine disorders. J Allergy Clin Immunol. 2003;111:S624–S636.

    Article  PubMed  CAS  Google Scholar 

  14. Peng H, Hagopian W. Environmental factors in the development of Type 1 diabetes. Rev Endocr Metab Disord. 2006;7:149–162.

    Article  PubMed  Google Scholar 

  15. Tracy S, Drescher KM. Coxsackievirus infections and NOD mice: relevant models of protection from, and induction of, type 1 diabetes. Ann N Y Acad Sci. 2007;1103:143–151.

    Article  PubMed  CAS  Google Scholar 

  16. Oikarinen M, Tauriainen S, Honkanen T, et al. Detection of enteroviruses in the intestine of type 1 diabetic patients. Clin Exp Immunol. 2008;151:71–75.

    Article  PubMed  CAS  Google Scholar 

  17. Frisk G, Fohlman J, Kobbah M, et al. High frequency of Coxsackie-B-virus-specific IgM in children developing type I diabetes during a period of high diabetes morbidity. J Med Virol. 1985;17:219–227.

    Article  PubMed  CAS  Google Scholar 

  18. Gamble DR, Taylor KW, Cumming H. Coxsackie viruses and diabetes mellitus. Br Med J. 1973;4:260–262.

    Article  PubMed  CAS  Google Scholar 

  19. Vaarala O. Is type 1 diabetes a disease of the gut immune system triggered by cow’s milk insulin?. Adv Exp Med Biol. 2005;569:151–156.

    Article  PubMed  Google Scholar 

  20. Harrison LC, Honeyman MC. Cow’s milk and type 1 diabetes: the real debate is about mucosal immune function. Diabetes. 1999;48:1501–1507.

    Article  PubMed  CAS  Google Scholar 

  21. Cavallo MG, Fava D, Monetini L, Barone F, Pozzilli P. Cell-mediated immune response to beta casein in recent-onset insulin-dependent diabetes: implications for disease pathogenesis. Lancet. 1996;348:926–928.

    Article  PubMed  CAS  Google Scholar 

  22. Monetini L, Cavallo MG, Manfrini S, et al. IMDIAB Group. Antibodies to bovine beta-casein in diabetes and other autoimmune diseases. Horm Metab Res. 2002;34:455–459.

    Article  PubMed  CAS  Google Scholar 

  23. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80:1678S–1688S.

    PubMed  CAS  Google Scholar 

  24. Chatfield SM, Brand C, Ebeling PR, Russell DM. Vitamin D deficiency in general medical inpatients in summer and winter. Intern Med J. 2007;37:377–382.

    Article  PubMed  CAS  Google Scholar 

  25. Stene LC, Ulriksen J, Magnus P, Joner G. Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia. 2000;43:1093–1098.

    Article  PubMed  CAS  Google Scholar 

  26. The EURODIAB Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for type l (insulin-dependent) diabetes mellitus. Diabetologia. 1999;42:51–54.

    Article  Google Scholar 

  27. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358:1500–1503.

    Article  PubMed  CAS  Google Scholar 

  28. Driver JP, Foreman O, Mathieu C, van Etten E, Serreze DV. Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D(3) and 1alpha-hydroxyvitamin D(3) on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet. Clin Exp Immunol. 2008;151:76–85.

    Article  PubMed  CAS  Google Scholar 

  29. McCarter RJ, Hempe JM, Chalew SA. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care. 2006;29:352–355.

    Article  PubMed  Google Scholar 

  30. Pozzilli P, Manfrini S, Picardi A. Cow’s milk and trials for prevention of Type 1 diabetes. Diabet Med. 2003;20:871–872.

    Article  PubMed  CAS  Google Scholar 

  31. TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr Diabetes. 2007;8:117–137.

    Article  Google Scholar 

  32. Lorini R, Minicucci L, Napoli F, Padovani P, Bazzigaluppi E, Tortoioli C, et al. Screening for type 1 diabetes genetic risk in newborns of continental Italy. Primary prevention (Prevefin Italy) – preliminary data. Acta Biomed Ateneo Parmense. 2005;76:31–35.

    Google Scholar 

  33. Buzzetti R, Galgani A, Petrone A, et al. Genetic prediction of type 1 diabetes in a population with low frequency of HLA risk genotypes and low incidence of the disease (the DIABFIN study). Diabetes Metab Res Rev. 2004;20:137–143.

    Article  PubMed  CAS  Google Scholar 

  34. Schmid S, Buuck D, Knopff A, Bonifacio E, Ziegler AG. BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with type 1 diabetes by delaying exposure to gluten. Diabetologia. 2004;47:1130–1131.

    Article  PubMed  CAS  Google Scholar 

  35. Kupila A, Sipila J, Keskinen P, et al. Intranasally administered insulin intended for prevention of type 1 diabetes – a safety study in healthy adults. Diabetes Metab Res Rev. 2003;19:415–420.

    Article  PubMed  CAS  Google Scholar 

  36. The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363:925–931.

    Article  Google Scholar 

  37. The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetologia. 2003;46:339–346.

    Article  Google Scholar 

  38. Bingley PJ, Gale EA. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia. 2006;49:881–890.

    Article  PubMed  CAS  Google Scholar 

  39. Pozzilli P, Andreani D. The potential role of nicotinamide in the secondary prevention of IDDM. Diabetes Metab Rev. 1993;9:219–230.

    Article  PubMed  CAS  Google Scholar 

  40. Elliott RB, Pilcher CC, Fergusson DM, Stewart AW. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab. 1996;9:501–509.

    Article  PubMed  CAS  Google Scholar 

  41. Kolb H, Burkart V. Nicotinamide in type 1 diabetes. Mechanism of action revisited. Diabetes Care. 1999;22(Suppl 2):B16–B20.

    PubMed  Google Scholar 

  42. Diabetes Prevention Trial Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685–1691.

    Article  Google Scholar 

  43. Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP. Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1. J Clin Endocrinol Metab. 2000;85:1255–1260.

    Article  PubMed  CAS  Google Scholar 

  44. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The diabetes prevention trial – type 1. Diabetes Care. 2005;28:1068–1076.

    Article  PubMed  CAS  Google Scholar 

  45. Bellmann K, Kolb H, Rastegar S, Jee P, Scott FW. Potential risk of oral insulin with adjuvant for the prevention of type 1 diabetes: a protocol effective in NODmice may exacerbate disease in BB rats. Diabetologia. 1998;41:844 –847.

    Article  PubMed  CAS  Google Scholar 

  46. http://www2.diabetestrialnet.org/

  47. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention: association of 1 year of cyclosporin treatment with enhanced insulin secretion. Diabetes. 1988;37:1574–1582.

    Article  Google Scholar 

  48. Martin S, Schernthaner G, Nerup J, et al. Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia. 1991;34:429–434.

    Article  PubMed  CAS  Google Scholar 

  49. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med. 1992;326:1654–1660.

    Article  PubMed  CAS  Google Scholar 

  50. Crino A, Schiaffini R, Ciampalini P, et al. IMDIAB Group. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2005;18:749–754.

    Article  PubMed  CAS  Google Scholar 

  51. Crino A, Schiaffini R, Manfrini S, et al. IMDIAB group. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Eur J Endocrinol. 2004;150:719–724.

    Article  PubMed  CAS  Google Scholar 

  52. Pozzilli P. IDDM preventive trials: what’s new?. Diabetes Metab Rev. 1998;14:260–261.

    Article  PubMed  CAS  Google Scholar 

  53. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692–1698.

    Article  PubMed  CAS  Google Scholar 

  54. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3- antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598–2608.

    Article  PubMed  CAS  Google Scholar 

  55. Mathieu C, van Etten E, Decallonne B, et al. Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. J Steroid Biochem Mol Biol. 2004;89–90:449–452.

    Article  PubMed  Google Scholar 

  56. Harris SS. Vitamin D in type 1 diabetes prevention. J Nutr. 2005;135:323–325.

    PubMed  CAS  Google Scholar 

  57. Pitocco D, Crinò A, Di Stasio E, et al. IMDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med. 2006;23:920–923.

    Article  PubMed  CAS  Google Scholar 

  58. Pitocco D, Di Stasio E, Crinò A, et al. Age at diagnosis of type 1 diabetes and the effect of immunomodulatory therapies on residual beta cell function. Horm Metab Res. 2007;40(1):66-68 Dec 18; (Epub).

    Article  PubMed  Google Scholar 

  59. Pozzilli P, Manfrini S, Crinò A, et al. IMDIAB Group. Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. Horm Metab Res. 2005;37:680–683.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank Juvenile Diabetes Research Foundation (JDRF), National Institute of Health (NIH) Consortia, Centro Internazionale Studi Diabete (CISD), Diabete e Metabolismo (DEM) Foundation, and University Campus Bio-Medico that support clinical research on T1D in our University Hospital.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy

    Paolo Pozzilli & Chiara Guglielmi M.D.

Authors
  1. Paolo Pozzilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Guglielmi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Pozzilli .

Editor information

Editors and Affiliations

  1. Div. Endocrinology & Metabolism, Beth Israel Medical Center, East 17th Street 317, New York, 10003, U.S.A.

    Leonid Poretsky

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pozzilli, P., Guglielmi, C. (2010). Prevention of Type 1 Diabetes Mellitus. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09841-8_49

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09841-8_49

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-09840-1

  • Online ISBN: 978-0-387-09841-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation